Thyrotropin Alfa
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Thyrotropin Alfa |
| DrugBank ID | DB00024 |
| Brand Names (EU) | Thyrogen |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.98% |
Approved Indication (EMA)
Thyrogen is indicated for use with serum thyroglobulin (Tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post thyroidectomy patients maintained on hormone suppression therapy (THST). Low risk patients with well-differentiated thyroid carcinoma who have undetectable serum Tg levels on THST and no rh (recombinant human) TSH-stimulated increase of Tg levels may be followed-up by assaying rh TSH-stimulated Tg
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | migraine disorder | 99.98% | DL |
| 2 | migraine with brainstem aura | 99.98% | DL |
| 3 | Raynaud disease | 99.96% | DL |
| 4 | migraine with or without aura, susceptibility to | 99.91% | DL |
| 5 | atrophoderma vermiculata | 99.86% | DL |
| 6 | ulerythema ophryogenesis | 99.84% | DL |
| 7 | pulmonary hypertension | 99.84% | DL |
| 8 | kyphoscoliotic heart disease | 99.81% | DL |
| 9 | postural orthostatic tachycardia syndrome | 99.69% | DL |
| 10 | hyperthyroidism | 99.65% | DL |
| 11 | hypotensive disorder | 99.57% | DL |
| 12 | resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta | 99.49% | DL |
| 13 | Graves disease | 99.46% | DL |
| 14 | Prinzmetal angina | 99.45% | DL |
| 15 | headache disorder | 99.44% | DL |
| 16 | sciatic neuropathy | 99.42% | DL |
| 17 | anaphylaxis | 99.38% | DL |
| 18 | cauda equina syndrome | 99.37% | DL |
| 19 | open-angle glaucoma | 99.35% | DL |
| 20 | hyperthyroxinemia | 99.32% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.